Cephalon expands pact on Celator delivery tech; NanoBioMagnetics wins SBIR grant;

> Cephalon is expanding its research pact with Celator, relying on Celator's nano-encapsulation delivery technology in its cancer drug development programs. Report

> NanoBioMagnetics has been awarded a Phase I Small Business Innovative Research grant from the National Science Foundation to study the effectiveness of magnetically vectored therapeutics in the treatment of locally advanced breast cancers. Release

> Quay Pharma's new purpose-designed laboratories and headquarters, which will focus on new drug delivery technologies as well as other research programs, have been officially opened by the Deputy First Minister of Wales. Release

> Celsion, which is developing oncology drugs using focused heat energy in combination with heat-activated drug delivery systems, has hired Jeffrey W. Church as vice president and CFO. Release

> Lipoxen's patent on its monofunctional PSA PolyXen technology has been extended. Report

And Finally... Researchers working on new devices that can be implanted in the human body to dispense therapeutics may want to learn more about the case of a British researcher whose virus-infected chip implanted in his hand was able to contaminate surrounding systems. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.